MUMBAI, India, Oct. 11 -- Intellectual Property India has published a patent application (202517091101 A) filed by Bavarian Nordic A/S, Hellerup, Denmark, on Sept. 23, for 'production of poxviruses from quail cell cultures.'
Inventor(s) include Schweneker, Marc; Hausmann, Jurgen; Kalla, Markus; Thrane, Susan Hoffmann; Falhof, Janus; Hertz, Henrik; and Andrea, Athina.
The application for the patent was published on Oct. 10, under issue no. 41/2025.
According to the abstract released by the Intellectual Property India: "The present invention relates to methods of producing poxvirus viral vector-based vaccine products from avian cell lines. In some embodiments, the avian cells are suspension quail cell lines. Pharmaceutical compositions such as vaccines produced by the methods of the invention are also provided. In some embodiments, the poxvirus viral vector is Modified Vaccinia Virus Ankara ("MVA") or recombinant MVA. In some embodiments, the recombinant MVA encodes heterologous antigens and can be used to produce a vaccine against the antigens. In some embodiments, the recombinant MVA encodes antigens of Respiratory Syncytial Virus (RSV) and the avian cells are used to produce a vaccine against RSV comprising the recombinant MVA and/or the encoded antigens."
The patent application was internationally filed on Mar. 07, 2024, under International application No.PCT/EP2024/056012.
Disclaimer: Curated by HT Syndication.
